Ibrutinib: a strong candidate for the future of mantle cell lymphoma treatment

References

• No authors listed. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. The Non-Hodgkin’s Lymphoma Classification Project. Blood 89(11), 3909–3918 (1997).
   PubMed Web of Science ®Google Scholar
• Salar A, Juanpere N, Bellosillo B et al. Gastrointestinal involvement in mantle cell lymphoma: a prospective clinic, endoscopic, and pathologic study. Am. J. Surg. Pathol. 30(10), 1274–1280 (2006).
   PubMed Web of Science ®Google Scholar
• Romaguera JE, Fayad LE, Feng L et al. Ten-year follow-up after intense chemoimmunotherapy with rituximab–HyperCVAD alternating with rituximab–high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma. Br. J. Haematol. 150(2), 200–208 (2010).
   PubMed Web of Science ®Google Scholar
• Takahashi Y, Mori J, Tanimoto T. Treatment of older patients with mantle-cell lymphoma. N. Engl. J. Med. 367(18), 1765; author reply 1765–1766 (2012).
   Google Scholar
• O’Connor OA, Wright J, Moskowitz C et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin’s lymphoma and mantle cell lymphoma. J. Clin. Oncol. 23(4), 676–684 (2005).
   PubMed Web of Science ®Google Scholar
• Witzig TE, Geyer SM, Ghobrial I et al. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J. Clin. Oncol. 23(23), 5347–5356 (2005).
   PubMed Web of Science ®Google Scholar
• Refaeli Y, Young RM, Turner BC, Duda J, Field KA, Bishop JM. The B cell antigen receptor and overexpression of MYC can cooperate in the genesis of B cell lymphomas. PLoS Biol. 6(6), e152 (2008).
   PubMedGoogle Scholar
• Dasmahapatra G, Patel H, Dent P, Fisher RI, Friedberg J, Grant S. The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib. Br. J. Haematol. 161(1), 43–56 (2013).
   PubMed Web of Science ®Google Scholar
• Advani RH, Buggy JJ, Sharman JP et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J. Clin. Oncol. 31(1), 88–94 (2013).
   PubMed Web of Science ®Google Scholar
• Wang M, Rule S, Martin P et al. Interim results of an international, multicenter, Phase 2 study of Bruton’s tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), in relapsed or refractory mantle cell lymphoma (MCL): durable efficacy and tolerability with longer follow-up. Presented at: ASH Annual Meeting. Atlanta, GA, USA, 8–11 December 2012 (Abstract 186).
   Google Scholar
• Wang M, Zhang L, Han X et al. A severe combined immunodeficient-hu in vivo mouse model of human primary mantle cell lymphoma. Clin. Cancer Res. 14(7), 2154–2160 (2008).
   PubMed Web of Science ®Google Scholar
• Honda F, Kano H, Kanegane H et al. The kinase Btk negatively regulates the production of reactive oxygen species and stimulation-induced apoptosis in human neutrophils. Nat. Immunol. 13(4), 369–378 (2012).
   PubMed Web of Science ®Google Scholar
• Di Paolo JA, Huang T, Balazs M et al. Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis. Nat. Chem. Biol. 7(1), 41–50 (2011).
   PubMed Web of Science ®Google Scholar
• Lee KG, Xu S, Kang ZH et al. Bruton’s tyrosine kinase phosphorylates Toll-like receptor 3 to initiate antiviral response. Proc. Natl Acad. Sci. USA 109(15), 5791–5796 (2012).
   PubMed Web of Science ®Google Scholar
• Zhang L, Yang J, Qian J et al. Role of the microenvironment in mantle cell lymphoma: IL-6 is an important survival factor for the tumor cells. Blood 120(18), 3783–3792 (2012).
   PubMed Web of Science ®Google Scholar
• Khare A, Viswanathan B, Gund R et al. Role of Bruton’s tyrosine kinase in macrophage apoptosis. Apoptosis 16(4), 334–346 (2011).
   PubMed Web of Science ®Google Scholar
• Kawakami Y, Inagaki N, Salek-Ardakani S et al. Regulation of dendritic cell maturation and function by Bruton’s tyrosine kinase via IL-10 and Stat3. Proc. Natl Acad. Sci. USA 103(1), 153–158 (2006).
   PubMed Web of Science ®Google Scholar
• Cyster JG. Chemokines and cell migration in secondary lymphoid organs. Science 286(5447), 2098–2102 (1999).
   PubMed Web of Science ®Google Scholar
• Corcione A, Arduino N, Ferretti E et al. CCL19 and CXCL12 trigger in vitro chemotaxis of human mantle cell lymphoma B cells. Clin. Cancer Res. 10(3), 964–971 (2004).
   PubMed Web of Science ®Google Scholar
• Kurtova AV, Tamayo AT, Ford RJ, Burger JA. Mantle cell lymphoma cells express high levels of CXCR4, CXCR5, and VLA-4 (CD49d): importance for interactions with the stromal microenvironment and specific targeting. Blood 113(19), 4604–4613 (2009).
   PubMed Web of Science ®Google Scholar